Drugs in Pregnancy – The Issues for 2010
Main Article Content
Keywords
.
Abstract
A Motherisk symposium on establishing benchmarks for the evaluation of medications during pregnancy, was held on May 10, 2006, under the auspices of the Canadian Society of Pharmacology and Therapeutics.1 From that symposium came a consensus on the need for collection and analysis of data on fetal safety and ongoing post-marketing surveillance, which in turn led to the establishment of CaseMed-Pregnancy – the Canadian Alliance for Safe and Effective Medication During Pregnancy and Breastfeeding.
References
1. Establishing a New Benchmark for Drug Evaluation during Pregnancy. Can J Clin Pharmacol 2007;14(1) Winter. http://www.cjcp.ca/pubmed.php?issueId=97 (Accessed August 2, 2010).
2. Witkop CT. New Prescription Drug Labeling Regulations and the Demise of “the Letter”. Obstet Gynecol 2009;114(3):502-3.
3. European Medicines Agency. Evaluation of Medicines for Human Use (London, July 24, 2008).http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=W
C500003307 (July 27, 2010).
2. Witkop CT. New Prescription Drug Labeling Regulations and the Demise of “the Letter”. Obstet Gynecol 2009;114(3):502-3.
3. European Medicines Agency. Evaluation of Medicines for Human Use (London, July 24, 2008).http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=W
C500003307 (July 27, 2010).